Recent studies have suggested that contraction of the smooth muscle in the cavernosal arterioles and in the walls of the cavernosal sinuses is maintained by the RhoA/Rho-kinase signaling pathway. However, this contraction activity must be overcome to permit the vasorelaxation essential for erection. We postulate that nitric oxide (NO) causes erection primarily by inhibiting the RhoA/Rho-kinase pathway. The following will discuss evidence in support of the important role of Rho-kinase-mediated vasoconstriction in the nonerect penis and how NO overrides this Rhokinase-mediated vasoconstriction to permit vasodilation and erection.
Introduction
The majority of the time, the smooth muscle cells in the erectile tissue remain contracted and blood flow into the cavernous sinuses is minimal. Studies from several laboratories strongly support the concept that RhoA/Rho-kinase-mediated vasoconstriction is primarily responsible for keeping penile smooth muscle in the contracted state. [1] [2] [3] [4] [5] Nitric oxide (NO), released by autonomic innervation and by endothelial cells leads to increased production of cGMP and activation of protein kinase G (PKG). We have proposed that the NO/cGMP/PKG pathway inhibits RhoA/Rho-kinase-mediated vasoconstriction allowing smooth muscle relaxation and the increased blood flow required for erection.
Erectile physiology 6 Erectile tissue is housed in the two dorsal corpora cavernosa and the single ventral corpus spongiosum of the penis. Since the spongiosum contributes little to the rigidity during erection, it will not be further discussed. The corpora cavernosa contain connective tissue arranged in a trabecular meshwork which is continuous with the tunica albuginea. This meshwork limits the system of vascular sinuses which are lined with endothelial cells (sinusoidal endothelial cells) and contains smooth muscle (sinusoidal smooth muscle) in their walls. Blood is conveyed out of the sinuses via the thin-walled veins lying immediately beneath the tunica albuginea (subtunical veins). The cavernosal arterioles also containing endothelial cells overlie layers of smooth muscle cells. When the arteriolar smooth muscle layer is contracted, only small volumes of blood are delivered to the sinuses and this volume is readily drained out through the subtunical veins. Thus, the contraction of arteriolar and sinusoidal smooth muscle limits blood flow into the erectile tissue and keeps the penis in the nonerect state. In order for erection to occur, the smooth muscle in the arterioles and cavernous sinuses must relax. As the arterioles relax, blood flow into the cavernous sinuses increases and exert shear and stretch force on the sinusoidal endothelial cells. The endothelial cells respond with the activation of eNOS activity and the release of additional NO which also contributes to smooth muscle relaxation. As the sinusoidal smooth muscle relaxes, the sinuses expand against the tunica albuginea and blood outflow decreases (veno-occlusion). The increased inflow and decreased outflow result in the high intracavernosal pressures which are characteristics of the erect penis.
VasoconstrictionFmaintenance of the penis in the flaccid state placed on the role of the RhoA/Rho-kinase calcium sensitization pathway. A more general description of penile pharmacology can be found in several recent reviews. [6] [7] [8] [9] The penis is held in the nonerect state except during periods of sexual excitement and during nocturnal penile tumescence events (nonsexual erections that occur during sleep). The contraction of penile smooth muscle appears to be mediated by the actions of a-adrenergic agonists and by the actions of endothelin-1 acting via ET A receptors. 8, 10, 11 The physiology of the ET B receptors in penile erection remains less clear. 12 In other vascular systems, 13 14 The intracellular Ca 2+ complexes with calmodulin, the complex binds to myosin light chain kinase (MLCK) resulting in its activation. When active, MLCK phosphorylates MLC permitting cross bridge formation and contraction. Besides this Ca 2+ -dependent contractile mechanism, there is also evidence for a Ca 2+ -independent mechanism operating to maintain smooth muscle contraction. This mechanism was suggested based on the observation that a simple relationship between [Ca 2+ ] i and agonist-induced force generation does not necessarily exist in vascular smooth muscle cells. 15 Agonist stimulation results in a transitory rise in calcium but [Ca 2+ ] i falls to near prestimulation levels even in the continued presence of the agonist and force generation. These experiments demonstrate that besides increasing [Ca 2+ ] i in a transient fashion, vasoconstrictor agents may increase the Ca 2+ sensitivity of the contractile apparatus. The Ca 2+ sensitization likely involves the RhoA/Rho-kinase regulation of MLC phosphatase activity. 16 
Vasorelaxation and erection of the penis
The penis becomes erect with the relaxation of arteriolar and sinusoidal smooth muscle. 7, 17 The principle agent leading to penile smooth muscle relaxation is NO released by the autonomic innervation of the erectile tissue and by arteriolar and cavernosal endothelial cells. 18 NO diffuses into smooth muscle cells where it activates soluble guanylate cyclase elevating intracellular levels of cyclic GMP and activating cyclic GMP-dependent protein kinase (PKG). 19 The NO/cGMP/PKG pathway is thought to reduce contractile activity by: (1) inhibiting L-type Ca 2+ channels, (2) activating Ca 2+ -dependent ATPase in the sarcoplasmic reticulum and/or (3) hyperpolarizing the cell membrane by causing increased opening of membrane K + channels. 20 RhoA/Rho-kinase calcium sensitization pathway ( Figure 1) While there is ample conceptual support for the importance of intracellular calcium in regulating vasoconstriction and vasodilation in the penile vasculature, Ca 2+ -sensitization has only recently been investigated in the erectile response. In other vascular tissues, Ca 2+ -sensitization is, in part, dependent on enzymes of the RhoA/Rho-kinase pathway. 14, 16, 19 RhoA is a small, GTP-binding protein that is involved in several cellular processes such as morphology, cytoskeletal function, secretion and smooth muscle contraction.
14 When RhoA is bound to GDP, it is inactive, but with heterotrimeric G-protein activation (from ligand binding), the GDP is exchanged for GTP. The RhoA-GTP undergoes post-translational geranylgeranylation and migration to the cell membrane in an active form. The process of activation of RhoA is regulated by three groups of proteins: guanine nucleotide dissociation inhibitors (GDI) inhibits RhoA activation, guanine nucleotide exchange factors (GEF) which promote the exchange of GDP for GTP to activate RhoA and GTPase associated proteins (GAP) which promote intrinsic GTPase activity to inhibit RhoA activation. Theoretically, factors that disrupt RhoA activation altering the activity of any of these proteins, by Figure 1 The RhoA/Rho-kinase pathway in the maintenance of smooth muscle contraction. RhoA is activated when it binds GTP, undergoes geranylgeranylation and migrates to the cell membrane. Activated RhoA activates Rho-kinase which catalyzes the phosphorylation (and inactivation) of MLC phosphatase. When MLC phosphatase is in the active form (ie, nonphosphorylated), it catalyzes the dephosphorylation of MLC and thereby promotes smooth muscle relaxation. In the penile circulation, smooth muscle relaxation leads to increased intracavernosal blood pressure and erection. 1, 5, 22 This pyridine derivative is thought to occupy the ATP binding site on Rho-kinase and thereby prevent the phosphorylation of MLC phosphatase. In the nonphosphorylated state, MLC phosphatase is active to remove the high-energy phosphate group from MLC and promote smooth muscle relaxation. Injection of Y-27632 into the cavernous sinuses of rats increases intracavernosal pressure (ICP) in a dose-dependent fashion. 22 Prior treatment with inhibitors of NOS or inhibitors of guanylate cyclase fails to alter the vasodilatory action of Y-27632 demonstrating that the Rho-kinase inhibitor does not activate NOdependent vasorelaxation to cause erection. Activation of the RhoA/Rho-kinase pathway appears to mediate the constrictor action of ET-1 and a-adrenergic agonists. In these studies, rats received an intracavernosal injection of methoxamine (a-adrenergic agonist) or endothelin-1 (both are potent vasoconstrictors in the cavernous circulation 12, 23, 24 ). However, the strong vasoconstrictor action of these agents was reversed by prior treatment with Y-27632 to inhibit RhoA/Rho-kinase activity. 1 These in vivo results suggest that the RhoA/Rho-kinase pathway mediates the vasoconstriction resulting from activation of both the aadrenergic or ET-1 pathways in the penile circulation. This concept is also supported by several in vitro studies in which strips of human, rabbit or rat cavernous tissue were contracted with phenylephrine or endothelin-1 and then caused to relax in a dose-dependent fashion with the addition of Y-27632. 3, 4, 21, 22 Based on these in vivo and in vitro studies, it can be suggested that the RhoA/Rhokinase pathway plays a critical role in the maintenance of the penis in the nonerect state. Furthermore, upregulation of this pathway could be a component in erectile dysfunction of several etiologies. 1, [3] [4] [5] 8, 21, 22, 25 It is of interest that strips of rabbit clitoris which have been contracted with phenylephrine relax with the addition of Y-27632 suggesting that the RhoA/Rho-kinase pathway may be important in the sexual response and sexual dysfunction in females as well. 26 Use of a dominant-negative form of RhoA in the investigation of the role of the RhoA/ Rho-kinase pathway in erection Additional proof supporting the importance of the RhoA/Rho-kinase pathway in the erectile response comes from the recent studies of Chitaley et al.
27
These experiments utilized the adeno-associated viral gene transfer of a dominant-negative RhoA mutant in penile tissue. The dominant-negative form of RhoA binds GTP and is modified and migrates to the cell membrane as normal. However, the dominant-negative RhoA fails to activate Rhokinase so that MLC phosphatase remains active to dephosphorylate MLCBP and smooth muscle relaxation occurs. When the dominant-negative RhoA was injected into the cavernosal sinuses of rats, smooth muscle cells were infected as demonstrated by Western analysis and immunohistochemistry. In the infected animals, basal intracavernosal pressure was significantly elevated and the erectile response to ganglionic stimulation was strongly enhanced. Systemic blood pressure was unaffected by the treatment. This novel finding strongly supports the hypothesis that the RhoA/Rho-kinase pathway is critically involved in the maintenance of the penis in the nonerect state and raises the possibility that the use of genetic inhibitors of RhoA activation could be of value in the treatment of erectile dysfunction.
RhoA/Rho-kinase mediated vasoconstriction must be overcome for erection to occur
Methoxamine and ET-1 are potent vasoconstrictors in the cavernosal circulation. 12, 28 However, vasoconstriction in response to these agents was prevented and erection was of normal magnitude when methoxamine or endothelin-1 was injected during electrically or NO-induced erection. 23, 24 This observation suggests that vasoconstrictor pathways are overcome during erection and raise the possibility that the primary action of NO leading to erection is to inhibit the vasoconstriction mediated by the RhoA/Rho-kinase pathway.
NO-dependent inhibition of RhoA/Rho-kinase-mediated vasoconstriction A review of the vascular smooth muscle literature revealed strong evidence for inhibition of RhoA/ Rho-kinase signaling by the NO/cGMP/PKG pathway in other vascular beds. Sauzeau et al 19 showed that NO-regulated vasodilation was due, in part, to the PKG-dependent phosphorylation of RhoA. The phosphorylation is thought to destabilize membrane binding of RhoA. Other studies 29 showed that rat aortic strips contracted in response to phenylephrine, but relaxed when treated with Y-27632 to inhibit Rho-kinase activity. However, if the strips were denuded of their endothelial layer (the primary source of NO in isolated aorta), Y-27632 was less effective at causing relaxation, but with the addition of a NO donor drug to the aortic strips, the relaxation effect of Y-27632 was fully restored. In other in vivo studies, the erectile response to a short-acting NO donor drug (NOR-1) was measured before and after administration of a threshold dose of Y-27632. 30 The very low dose of Y-27632 significantly enhanced the erectile response to the NO donor drug and further, the response to the combination of the two drugs (ie, NO donor drug plus Y-27632) was significantly greater than that of the response to either drug alone or to the sum of the individual responses (Figure 2 ). Taken together, these various lines of investigation strongly support the hypothesis that NO/cGMP/ PKG-mediated vasodilation leading to erection involves inhibition of RhoA/Rho-kinase-regulated vasoconstriction. 22 
Conclusions
Studies of the erectile process have demonstrated that the penis is maintained in the nonerect state by activity of the RhoA/Rho-kinase pathway. The activity of this pathway maintains the state of contraction of arteriolar and sinusoidal smooth muscle to limit blood flow and keeps the penis flaccid. We have proposed that the principle action of NO leading to erection is by inhibiting the RhoA/ Rho-kinase signaling pathway to permit smooth muscle. With relaxation of the arteriolar smooth muscle, blood flows into the cavernous sinuses exerting shear and stretch force to stimulate eNOS activity and further relaxation. As the sinusoidal smooth muscle relaxes, blood fills the sinuses to activate veno-occlusion and results in erection. 
